Literature DB >> 17938258

Formyl peptide receptor-like 1 mediated endogenous TRAIL gene expression with tumoricidal activity.

Chentao Lin1, Wei Wei, Jinchun Zhang, Shilian Liu, Yanxin Liu, Dexian Zheng.   

Abstract

Formyl peptide receptor-like 1 (FPRL1), which is a G protein-coupled receptor of chemoattractant subfamily, plays an important role in the regulation of host defense against pathogenic infection and the chemotactic and activating effects of Abeta42 on mononuclear phagocytes as well as in the elimination of damaged or pathogen-infected cells. In the present study, we showed that stimulation of FPRL1 agonist ligands (W peptide from a synthetic peptide library, N36 peptide from HIV-1 gp41, and F peptide from HIV-1 envelope protein gp120) elevated endogenous tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression in human THP-1 monocytes, primary neutrophils, and mouse leukocytes. Activation of nuclear factor kappaB was required by the FPRL1-mediated TRAIL expression in the human THP-1 cells and primary neutrophils. The increased TRAIL expression in the mice significantly suppressed the growth of transplanted mouse liver tumor cells by inducing apoptotic cell death. Together, these data provide novel evidence for the physiologic role of FPRL1 and TRAIL in tumor immune surveillance and innate immunity, and implicate a novel strategy for cancer therapy by triggering the endogenous TRAIL expression via stimulation of G protein-coupled receptor FPRL1.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17938258     DOI: 10.1158/1535-7163.MCT-07-0286

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  6 in total

1.  Duplex high-throughput flow cytometry screen identifies two novel formylpeptide receptor family probes.

Authors:  Susan M Young; Cristian M Bologa; Dan Fara; Bj K Bryant; Juan Jacob Strouse; Jeffrey B Arterburn; Richard D Ye; Tudor I Oprea; Eric R Prossnitz; Larry A Sklar; Bruce S Edwards
Journal:  Cytometry A       Date:  2009-03       Impact factor: 4.355

Review 2.  Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition.

Authors:  I A Schepetkin; A I Khlebnikov; M P Giovannoni; L N Kirpotina; A Cilibrizzi; M T Quinn
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

Review 3.  Transcriptional regulation of tumour necrosis factor-related apoptosis-inducing ligand.

Authors:  Nor Saadah M Azahri; Mary M Kavurma
Journal:  Cell Mol Life Sci       Date:  2013-01-18       Impact factor: 9.261

4.  Identification of novel small-molecule agonists for human formyl peptide receptors and pharmacophore models of their recognition.

Authors:  Liliya N Kirpotina; Andrei I Khlebnikov; Igor A Schepetkin; Richard D Ye; Marie-Josèphe Rabiet; Mark A Jutila; Mark T Quinn
Journal:  Mol Pharmacol       Date:  2009-11-10       Impact factor: 4.436

5.  Mannan-modified Ad5-PTEN treatment combined with docetaxel improves the therapeutic effect in H22 tumor-bearing mice.

Authors:  Zhongbing Liu; Jinwei Li; Juan Li; Juan Huang; Famin Ke; Qiaona Qi; Xing Jiang; Zhirong Zhong
Journal:  Int J Nanomedicine       Date:  2012-09-17

Review 6.  Distinct signaling cascades elicited by different formyl peptide receptor 2 (FPR2) agonists.

Authors:  Fabio Cattaneo; Melania Parisi; Rosario Ammendola
Journal:  Int J Mol Sci       Date:  2013-04-02       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.